Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/172145
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sanjosé Llongueras, Silvia de | - |
dc.contributor.author | Serrano, Beatriz | - |
dc.contributor.author | Tous, Sara | - |
dc.contributor.author | Alejo, Maria | - |
dc.contributor.author | Lloveras Rubio, Betlem | - |
dc.contributor.author | Quirós, Beatriz | - |
dc.contributor.author | Clavero, Omar | - |
dc.contributor.author | Vidal-Bel, August | - |
dc.contributor.author | Ferrándiz Pulido, Carla | - |
dc.contributor.author | Pavón Ribas, Miquel Àngel | - |
dc.contributor.author | Holzinger, Dana | - |
dc.contributor.author | Halec, Gordana | - |
dc.contributor.author | Tommasino, Massimo | - |
dc.contributor.author | Quint, Wim | - |
dc.contributor.author | Pawlita, Michael | - |
dc.contributor.author | Muñoz, Nubia | - |
dc.contributor.author | Bosch José, Francesc Xavier, 1947- | - |
dc.contributor.author | Alemany i Vilches, Laia | - |
dc.contributor.author | RIS HPV TT, VVAP and Head and Neck study groups | - |
dc.date.accessioned | 2020-11-18T09:20:19Z | - |
dc.date.available | 2020-11-18T09:20:19Z | - |
dc.date.issued | 2018-11-01 | - |
dc.identifier.issn | 2515-5091 | - |
dc.identifier.uri | http://hdl.handle.net/2445/172145 | - |
dc.description.abstract | Background: Many countries, mainly high- and upper-middle income, have implemented human papillomavirus (HPV) vacci- nation programs, with 47 million women receiving the full course of vaccine (three doses) in 2014. To evaluate the potential impact of HPV vaccines in the reduction of HPV-related disease, we aimed to estimate the HPV type distribution and burden of anogenital and head and neck cancers attributable to HPV types (HPVs 16/18/31/33/45/52/58/6/11) included in currently licensed HPV vaccines. Methods: In all, 18 247 formalin-fixed paraffin-embedded specimens were retrieved from 50 countries. HPV DNA detection and typing were performed with the SPF-10 PCR/DEIA/LiPA25 system. With the exception of cervical cancer, HPV DNA- positive samples were additionally subjected to HPV E6*I mRNA detection and/or p16INK4a immunohistochemistry. For cervi- cal cancer, estimates were based on HPV DNA, whereas for other sites, estimates were based on HPV DNA, E6*I mRNA, and p16INK4a biomarkers. Results: The addition of HPVs 31/33/45/52/58 to HPVs 16/18/6/11 in the nonavalent HPV vaccine could prevent almost 90% of cervical cancer cases worldwide. For other sites, the nonavalent HPV vaccine could prevent 22.8% of vulvar, 24.5% of penile, 60.7% of vaginal, 79.0% of anal cancers, 21.3% of oropharyngeal, 4.0% of oral cavity, and 2.7% of laryngeal cancer cases. Conclusions: Our estimations suggest a potential impact of the nonavalent HPV vaccine in reducing around 90% of cervical cancer cases and a global reduction of 50% of all the cases at HPV-related cancer sites. | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Oxford University Press | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1093/jncics/pky045 | - |
dc.relation.ispartof | JNCI Cancer Spectrum, 2018, vol. 2, num. 4, p. pky045 | - |
dc.relation.uri | https://doi.org/10.1093/jncics/pky045 | - |
dc.rights | cc by-nc (c) Sanjosé Llongueras et al., 2018 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es | - |
dc.source | Articles publicats en revistes (Patologia i Terapèutica Experimental) | - |
dc.subject.classification | Papil·lomavirus | - |
dc.subject.classification | Càncer de coll uterí | - |
dc.subject.other | Papillomaviruses | - |
dc.subject.other | Cervix cancer | - |
dc.title | Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58 | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 683951 | - |
dc.date.updated | 2020-11-18T09:20:19Z | - |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/FP7/282562/EU//HPV-AHEAD | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 31360870 | - |
Appears in Collections: | Articles publicats en revistes (Patologia i Terapèutica Experimental) Publicacions de projectes de recerca finançats per la UE Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
683951.pdf | 2.97 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License